Posts in Business
U.S. Companies and Groups to Congress: the Section 101 Reform Draft is Good and Genes are Safe
Seventy-two companies and organizations, ranging from Tivo to Bristol-Myers Squibb and from the American Conservative Union to the Alliance of U.S. Startups & Inventors for Jobs (USIJ)— …
After Brunetti: The Trademark Bar Reacts to Fractured Decision
The Supreme Court issued its decision yesterday in Iancu v. Brunetti. As largely expected, the Court followed its own lead in Matal v. Tam and struck down …
This Week on Capitol Hill: SCOTUS Grants Cert in Two IP Cases and Strikes Down Bar on Immoral/ Scandalous Marks; Plus, AI in Counterterrorism and Fintech, Copyright Office Oversight
This week on Capitol Hill and vicinity, the Supreme Court issues its decision in Iancu v. Brunetti and issues orders in several other IP cases. Meanwhile, various …
USPTO Commissioner for Patents on Life Five Years After Alice: We’ve Come a Long Way
Panelists in this past Thursday’s IPWatchdog webinar, “Dissecting Alice,” gave credit to the U.S. Patent and Trademark Office (USPTO) for the steps it has taken …
Inventors Must Oppose the Draft Section 101 Legislation
When it was announced that I would be testifying to the Senate Judiciary Subcommittee on IP about Section 101, I was surprised. Not only did they grant a …
Other Barks & Bites, Friday June 21: China Releases National IP Strategy, Iancu Discusses Patent Eligibility, and Rubio Amendment Would Prevent Huawei Patent Suits
This week in Other Barks & Bites: Senators Tillis and Coons ask federal agencies to step up enforcement against IP theft; Senator Stabenow and Congressman Cummings ask GAO …
Gene Quinn Named Top IP Strategist by IAM For Third Consecutive Year
Gene Quinn, IPWatchdog Founder and CEO, has been named to the IAM Strategy 300 – The World’s Leading IP Strategists for the third consecutive year. The IAM Strategy 300 “…
Congress Adds TERM Act and No Combination Drug Patents Act to List of Drug Patent Bills Being Considered
The growing debate over the effects of patents on the rising price of pharmaceuticals continues to encourage the introduction of drug pricing-focused bills in Congress over the …
After Alice: IP Stakeholders Comment on Alice’s Impact Five Years On
Since the Supreme Court issued its decision in Alice v. CLS Bank five years ago today, patent eligibility jurisprudence and practice have become increasingly chaotic—at least …
Perspective: Weakening Alice Will Weaken the U.S. Patent System’s Second Engine of Innovation
Today is Alice’s fifth birthday; some may not be celebrating, but as a birthday gift, John Vandenberg argues the decision was not new law and should …
Federal Circuit Issues Precedential Decisions On Who Can Petition for and Who Can Be Subject to Inter Partes Review
Late last week, the Federal Circuit issued Power Integrations, Inc. v. Semiconductor Components Indus., LLC and Regents of the Univ. of Minnesota v. LSI Corp. These two …
The Only Way to Counter False Claims on Patent Reform is to Enter the Debate
Coverage of the ongoing patent reform debate in the Senate Judiciary Committee by the popular press has been alarmist and largely incorrect. For example, even just yesterday—…
This Week on Capitol Hill: Drone Security Developments, Clean Energy Innovations, and Think Tanks Look at Patent Reform and Drug Pricing
This week, the U.S. Senate will hold hearings on enhancing drone innovation and addressing cybersecurity concerns; reducing prescription drug prices; and developments in geothermal energy technologies. …
Forging Ahead After Losing an Alice Appeal
It’s tough to fight on after losing an Alice appeal, but that’s just what most applicants are doing. An “Alice appeal” is an appeal of …
A Look at Google’s Patent Applications for Light Field Technology
Google’s U.S. patent application 20190124318—originally assigned to Lytro, an American developer of light-field cameras, before it went defunct in March 2018—was published in April 2019. Google …
